Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
Rachel Cusatis(Medical College of Wisconsin), Surbhi Sidana(Centro de Investigación del Cáncer), Irena Tan(Stanford Medicine), Emma Crawford(Stanford University), Matthew J. Frank, Anita D’Souza, Idayat Akinola(Medical College of Wisconsin), Kathryn E. Flynn(Medical College of Wisconsin), Claire Piehowski(Medical College of Wisconsin), Jennifer M. Knight(Medical College of Wisconsin), Juliana Craig(Stanford Medicine), David B. Miklos(Cancer Prevention Institute of California), Lori Muffly(Stanford University), Nirav N. Shah(Medical College of Wisconsin), Aline Thiengmany(Stanford University)
Cited by 19
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
|Blood|2017|296
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266